New nanoparticle drug aims to fight tough lung cancer
NCT ID NCT07391813
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug called SNB-101, a nanoparticle version of a chemotherapy agent, in people with extensive stage small cell lung cancer that has progressed after standard treatment. The trial has two phases: phase 1 checks safety and the best dose, while phase 2 looks at how well the drug works. About 55 participants will receive the drug by IV on days 1 and 15 of each 28-day cycle.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SNB-101 (a nanoparticle form of the chemotherapy drug SN-38)
- What this could lead to
- If successful, this could provide a new treatment option for people with advanced small cell lung cancer who have not responded to standard therapies.
- What could go wrong
- This is an early-phase trial with only 55 participants, so results may not apply broadly. The drug may cause significant side effects or fail to shrink tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PATIENT IS NOT SUITABLE FOR COMPLETE SURGICAL RESECTION WITH A CYTOLOGICALLY OR HISTOLOGICALLY CONFIRMED SMALL CELL LUNG CANCER(SCLC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Institute for Pulmonary Diseases of Vojvodina
RECRUITINGKamenitz, 21204, Serbia